open access

Vol 71, No 1 (2020)
Clinical Vignette
Published online: 2019-10-23
Submitted: 2019-08-25
Accepted: 2019-10-06
Get Citation

Life-threatening hypophosphataemia secondary to zoledronic acid implementation in a middle-age patient who presented with advanced osteolysis in the course of multiple myeloma

Mikołaj Radziszewski, Anna Karpiłowska, Joanna Podgórska, Anna Ziółkowska, Michał Popow
DOI: 10.5603/EP.a2019.0048
·
Pubmed: 31681977
·
Endokrynologia Polska 2020;71(1):100-101.

open access

Vol 71, No 1 (2020)
Clinical Vignette
Published online: 2019-10-23
Submitted: 2019-08-25
Accepted: 2019-10-06

Abstract

Not required for Clinical Vignette.

Abstract

Not required for Clinical Vignette.

Get Citation

Keywords

hypophosphatemia; zoledronic acid; osteolysis; multiple myeloma

About this article
Title

Life-threatening hypophosphataemia secondary to zoledronic acid implementation in a middle-age patient who presented with advanced osteolysis in the course of multiple myeloma

Journal

Endokrynologia Polska

Issue

Vol 71, No 1 (2020)

Pages

100-101

Published online

2019-10-23

DOI

10.5603/EP.a2019.0048

Pubmed

31681977

Bibliographic record

Endokrynologia Polska 2020;71(1):100-101.

Keywords

hypophosphatemia
zoledronic acid
osteolysis
multiple myeloma

Authors

Mikołaj Radziszewski
Anna Karpiłowska
Joanna Podgórska
Anna Ziółkowska
Michał Popow

References (6)
  1. Delorme S, Baur-Melnyk A. Imaging in multiple myeloma. Recent Results Cancer Res. 2011; 183: 133–147.
  2. Harmer D, Falank C, Reagan MR. Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma. Front Endocrinol (Lausanne). 2018; 9: 788.
  3. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733–759.
  4. Chiam P, Manju C, Chiam P, et al. Profound and protracted hypophosphatemia after a single dose of zoledronic acid infusion for osteoporosis associated with normocalcemic primary hyperparathyroidism. Med Case Rep. 2017; 3: 1–4.
  5. Torimoto K, Okada Y, Arao T, et al. A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. Endocr J. 2012; 59(12): 1051–1056.
  6. Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem. 1998; 35 ( Pt 2): 201–206.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl